Topical decitabine - ViMREX
Alternative Names: VTD-101; VTD-101 ointmentLatest Information Update: 10 Mar 2023
At a glance
- Originator ViMREX
- Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Vulvar intraepithelial neoplasia
Most Recent Events
- 22 Feb 2023 Phase-I clinical trials in Vulvar intraepithelial neoplasia (Newly diagnosed, Second-line therapy or greater, Recurrent) in Germany (Topical) (NCT05717621)
- 08 Feb 2023 Preclinical trials in Vulvar intraepithelial neoplasia in Germany (Topical) before February 2023
- 08 Feb 2023 ViMREX plans a phase-I trial for Vulvar intraepithelial neoplasia (Recurrent, Newly diagnosed, Second-line therapy or greater) in February 2023 (Topical) (NCT05717621)